CTOs on the Move

Meadowmere Assisted Living

www.meadowmere-wi.com

 
Meadowmere Assisted Living is a Madison, WI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details

Similar Companies

STATPROBE

STATPROBE is a Ann Arbor, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Grifols

Grifols is a global healthcare company whose mission is to improve the health and well being of people around the world. We accomplish this mission by producing life-saving protein therapies for patients and by providing hospitals, pharmacies and healthcare professionals with the tools they need to deliver expert medical care. We have three primary divisions Bioscience, Diagnostic and Hospital – which develop, produce and market our innovative products and services to medical professionals in more than 90 countries around the world.

Onnit

Get the supplements, nutrient-dense and Earth-grown foods, and fitness equipment to achieve your next level of well-being and Total Human Optimization.

Golden Years Medical Inc

Golden Years Medical Inc is a San Francisco, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Foghorn Therapeutics

More than 20,000 genes make us human. Genes control critical aspects of health and disease — but what controls our genes? Foghorn® Therapeutics ($FHTX) is developing therapies based on a system that directs which genes our cells express, and when, where, and in what order. By manipulating this system with our unique Gene Traffic Control™ platform, Foghorn will change how genes turn “on” and “off.” Unlike approaches that edit genes, this novel way of thinking will alter what our DNA has in store for us—and rewrite destiny for millions of people living with disease. With Gene Traffic Control™ Foghorn is pioneering a new, major class of drug targets to develop unprecedented therapies for cancer and other serious diseases. We have already validated multiple targets, are in the process of developing drug candidates in multiple types of cancer and are beginning to explore other diseases.